Methylene Blue

Clinical Summary

Methylene blue (methylthioninium chloride, MB) is a phenothiazine-derived redox-cycling cation first synthesized in 1876 by Heinrich Caro and used as a textile dye, biological stain, and antimalarial. It is FDA-approved as USP-grade injection for acquired methemoglobinemia (1–2 mg/kg IV; AHA 2023 first-line per PMID 37721023), where it serves as an electron acceptor that reduces ferric iron in oxidized hemoglobin back to the ferrous form. It is also approved as a surgical tissue stain. The "nootropic" / "mitochondrial" supplementation use case is entirely off-label and rests on a much thinner evidence base than the methemoglobinemia indication.

The strongest single piece of human supplementation evidence in the cognitive-enhancement / neurodegeneration domain is the Wischik et al. Phase 2 trial of LMTX (a stabilized methylthioninium derivative) in mild-to-moderate Alzheimer disease (PMID 25027327, Wischik et al. 2015), which reported a dose-dependent reduction in cognitive decline (ADAS-cog) at 138 mg BID over 50 weeks in monotherapy patients (n=321). Two subsequent Phase 3 trials of LMTM (TRx0237) in Alzheimer disease and behavioral-variant frontotemporal dementia (NCT01689246, NCT01689233, NCT01626378) failed to meet primary endpoints in the overall intention-to-treat analysis. The successor compound HMTM (hydromethylthionine mesylate, the active leuco-form metabolite) was tested in the LUCIDITY Phase 3 trial in MCI + mild-moderate AD; TauRx claims positive results (PMID 41570392, March 2026 readout) but independent verification is pending. A 2024 finding (PMID 38677558, Schwab et al.) that cholinesterase inhibitors (donepezil) interfere with HMTM benefit retrospectively explains the LMTM Phase 3 failures in patients on standard AD therapy.

The septic shock / vasoplegia indication has matured substantially in 2024. Multiple meta-analyses (Fernando 2024 PMID 38904978; Pruna 2024 PMID 37880041; Bauer 2025 PMID 39965613) report point estimates favoring MB for mortality (RR ~0.81 in pooled septic shock data) at 1–2 mg/kg IV, with low-to-moderate certainty due to heterogeneous dosing and small RCTs. The Surviving Sepsis Campaign does NOT explicitly endorse MB as standard-of-care; it remains adjunctive rescue therapy. The first human RCT signal in postoperative delirium (PMID 40696945, 2025) — intraoperative MB reduces postop delirium incidence in elderly joint-replacement surgery — is a notable cognition-protective signal independent of the AD/TBI literature.

The supplement-marketing claim that low-dose oral methylene blue produces cognitive enhancement, mitochondrial rescue, or photobiomodulation-style benefits in healthy adults rests primarily on (a) preclinical rodent work showing low-dose hormetic effects on mitochondrial cytochrome c oxidase (Atamna et al.), (b) small fMRI / memory studies in healthy adults using single-dose oral MB, and (c) extrapolation from the LMTX/LMTM/HMTM Alzheimer program. This is mechanistic extrapolation, not replicated clinical efficacy.

Who might benefit: patients with acquired methemoglobinemia (FDA-approved indication, hospital setting, IV dosing). Patients in refractory septic shock or vasoplegia under medical supervision. Patients enrolled in registered tauopathy trials. There is no validated supplementation indication in healthy adults, and the off-label use carries non-trivial drug-interaction risk (serotonergic agents) and quality-control risk (lab-grade vs USP-grade purity).

Indications & Evidence

Reading this table: Stars = evidence volume. Type = causal taxonomy. BH = Bradford Hill /9. Safety: -- no signals | MON monitor (known AEs, manageable) | WARN serious FAERS signals.

Hard rule: Star rating cannot exceed Type ceiling. UCC caps at 3/5, OA at 3/5, ME at 2/5, NE at 1/5.

Type codes: DC=Direct causation | PC=Probable | UCC=Unreplicated causal | BC=Biomarker correlation | SE=Surrogate endpoint | ME=Mechanistic extrapolation | AHE=Animal→human | OA=Observational | NE=No evidence

Prescribing

Methemoglobinemia (FDA-approved, hospital):

• USP-grade IV solution (Provayblue NDA204630 or generics: Meitheal, Zydus, Xiromed, Hikma, SteriScience, Chengdu Shuode, Nexus)
• 1–2 mg/kg IV slow push over 5 min
• Repeat at 30–60 min if symptomatic methemoglobinemia persists
• Cumulative max ~7 mg/kg (above this, paradoxical methemoglobinemia from oxidative load)
• Pediatric dosing same per kg from ≥3 months age
• AHA 2023 endorses as first-line antidote for symptomatic acquired methemoglobinemia (PMID 37721023)

Septic shock vasoplegia (off-label, ICU):

• 1–2 mg/kg IV bolus
• Optional infusion 0.25–1 mg/kg/h × 6–48 h
• Adjunctive only — Surviving Sepsis Campaign does NOT endorse as standard-of-care

Off-label nootropic (no clinical guidance):

• Community range: microdose 60 mcg–1 mg/d → standard biohacker 5–16 mg/d → "longevity" 10–30 mg/d
• Highest community-cycling pattern: 5 days on / 2 days off
• USP-grade only — see Purity section
• Pre-screen G6PD status; review all medications for serotonergic interactions

Mechanism

Redox cycling (the central pharmacology): Methylene blue exists in two interconverting forms — oxidized MB (blue, cation) and reduced leuco-methylene blue / leucomethylene blue / LMB (colorless). It accepts electrons from NADH and NADPH and donates them to molecular oxygen, ferric iron, and other electron acceptors. This single property explains the bulk of its observed effects across very different clinical contexts: methemoglobin reduction, mitochondrial electron-transport bypass, nitric-oxide / soluble guanylate cyclase inhibition, and photodynamic singlet-oxygen generation under light.

Methemoglobin reduction (the FDA-approved mechanism): MB is reduced by NADPH-methemoglobin reductase to leuco-MB, which then non-enzymatically donates electrons to Fe³⁺ in methemoglobin, regenerating Fe²⁺ hemoglobin. This is why the indication requires functional G6PD (NADPH supply) — G6PD-deficient patients cannot generate the leuco-MB and instead suffer hemolysis from oxidative stress. Emadi et al. 2025 (PMID 37694789) propose pre-reduced leucomethylene blue as a G6PD-safe alternative bypassing NADPH dependency (preclinical/conceptual).

Mitochondrial electron-transport bypass (the proposed nootropic mechanism): At low doses (sub-µM in vitro; ~0.5–4 mg/kg oral in vivo), MB is hypothesized to bypass complex I/III bottlenecks by accepting electrons from NADH and donating them directly to cytochrome c, increasing cytochrome c oxidase activity and ATP output. Atamna et al. (PMID 18230223, FASEB J 2008) reported that low-dose MB delayed cellular senescence and increased complex IV activity ~30% in IMR90 fibroblasts and rat brain mitochondria, while higher concentrations inhibited respiration — establishing the hormetic dose-response curve in cell and rodent systems. The clinical relevance of this mechanism in healthy human cognition is unproven.

Tau aggregation inhibition + redox crosslinking (the LMTX/LMTM/HMTM rationale, refined 2024): Original framing: MB inhibits tau-tau filament assembly in vitro and reduces tau pathology in transgenic mouse models. Refined mechanism (PMID 39055157, Seo et al. 2024 JACS Au, Korean): MB induces disulfide bond formation between Cys residues on tau, oxidatively crosslinking it. This reframes "anti-aggregation" as redox-mediated covalent modification rather than stoichiometric blockade. Cranston et al. 2024 (PMID 38909930) showed HMTM rescues synaptosomal glutamate release in tau transgenic mice. The Wischik program developed LMTX → LMTM → HMTM (the reduced leuco-form, with better oral bioavailability and reduced GI/urinary chromaturia) for AD and FTD.

Cholinesterase-inhibitor interference (PMID 38677558, Schwab et al. 2024): Cholinesterase inhibitors (donepezil) interfere with HMTM's rescue of synaptosomal glutamate release and SNARE proteins in tau transgenic mice. This retrospectively explains the failed LMTM Phase 3 in patients on standard AD therapy (most patients were on donepezil) and why the monotherapy subgroup signal persisted. LUCIDITY (HMTM Phase 3, 2026) was designed around this finding.

Monoamine oxidase A inhibition (the serotonin-syndrome mechanism): MB is a potent reversible inhibitor of MAO-A. Ramsay, Dunford & Gillman (PMID 21422984, Br J Pharmacol 2007) measured the Ki for MAO-A at ~5 nM and confirmed that the in-vivo doses used for parathyroid surgery (1–7.5 mg/kg IV) produce plasma concentrations far above the MAO-A inhibition threshold. Co-administration with serotonergic drugs (SSRIs, SNRIs, MAOIs, triptans, tramadol, meperidine, dextromethorphan, St. John's Wort, linezolid) can precipitate serotonin syndrome. The FDA Provayblue label carries a boxed-equivalent warning (5.1) and mandates a 72-hour serotonergic-agent washout before non-emergency MB use.

Soluble guanylate cyclase / NO inhibition (the vasoplegia mechanism): MB inhibits soluble guanylate cyclase and nitric oxide synthase, reducing cGMP-mediated vasodilation. This explains the MAP-elevating effect in vasoplegic / septic shock states. Spiess 2026 (PMID 41266160) reframes vasoplegia mechanism as broader oxidation-reduction dysregulation, beyond simple sGC/NOS inhibition.

Neuroinflammation suppression + BBB repair (the postop delirium mechanism): Deng et al. 2025 (PMID 41298550) demonstrated MB reduces postoperative delirium via neuroinflammation suppression and blood-brain barrier repair in mouse models — distinct from the electron-shuttle bypass mechanism and consistent with the Zhang 2025 (PMID 40696945) RCT signal.

Pharmacokinetics

Oral bioavailability is approximately 70% in fasted adults (varies with formulation; the LMTM/HMTM leuco-form has improved oral PK over MB cation). Tmax ~1–2 hours after oral dosing. Volume of distribution is large (~250 L) reflecting tissue accumulation. Plasma protein binding is moderate (~50–80%). Metabolism: extensive first-pass reduction to leuco-MB (the redox couple cycles in vivo); leuco-MB is glucuronidated and excreted in urine (giving the characteristic blue-green urine — a pharmacodynamic marker, not toxicity). Plasma elimination half-life is ~5–6 hours but tissue half-life is longer due to redox recycling. Brain penetration occurs (MB crosses the BBB; brain-to-plasma ratio ~1–10 in animal models). At standard supplementation doses, blue urine and tongue/saliva discoloration appear within hours and resolve within 1–3 days after discontinuation. The 2025 LC-QToF-MS method (PMID 40254552, Korean) using difluoroacetic acid offers improved analytical quantification for clinical PK studies.

Safety

FAERS Signal Table (suspect-only, top 10 of 1,769 reports)

Total: 1,829 reports (1,769 suspect / 60 concomitant) | 208 death-outcome suspect-only. Top death-leading reactions: cardiac arrest, circulatory collapse, respiratory failure, vasoplegia syndrome, depressed consciousness.

FDA Boxed-Equivalent Warnings (Provayblue label, 2024-12-02 supplement)

• 5.1 Serotonin syndrome — co-administration with serotonergic drugs/opioids; 72-hour washout mandate
• 5.2 Anaphylactic / anaphylactoid reactions
• 5.3 Lack of effectiveness or rebound with aniline/sulfa-induced methemoglobinemia
• 5.4 Hemolytic anemia in G6PD deficiency — CONTRAINDICATED in G6PD deficiency
• Pulse oximetry interference (transient false desaturation during/after dosing)
• Bispectral index (BIS) monitor depression
• Urine dipstick interference

Other Clinically Reported

• Mild GI upset (nausea, abdominal discomfort) at oral doses >2 mg/kg
• Headache, dizziness
• Skin discoloration (transient blue)
• Mouth, tongue, teeth staining (community-reported #1 nuisance complaint)
• Photosensitization at high doses (singlet-oxygen generation under light)
• Cutaneous heat hyperalgesia at higher topical doses (PMID 38773702 — rat model contradicts blanket "skin-safe topical" framing)

Theoretical Concerns

• Mitochondrial dose-response inversion: Low-dose MB increases mitochondrial respiration; high-dose MB inhibits complex I/IV. The "more is better" intuition is false. Chronic high-dose oral supplementation could in principle move from hormetic stimulation to mitochondrial inhibition; not well-characterized in humans.
• Pregnancy: IV MB has been associated with intestinal atresia in fetuses when used as a tracer in second-trimester amniocentesis — contraindicated in pregnancy except for life-threatening methemoglobinemia.

Special Populations

• G6PD-deficient: CONTRAINDICATED (FDA 5.4). Hemolytic anemia. MB cannot complete redox cycle without NADPH and instead drives oxidative damage. Pre-screen G6PD status before non-emergency use; prevalence 5–25% in Mediterranean / African / Southeast Asian populations.
• Pregnancy: Contraindicated except life-threatening methemoglobinemia (intestinal atresia signal in 2nd-trimester amniocentesis exposure).
• Pediatric ≥3 months: Provayblue label permits 1–2 mg/kg IV for methemoglobinemia.
• Concurrent serotonergic medications: Serotonin syndrome risk; FDA mandates 72-hour washout.

What FAERS Tells Us (and the Noise)

FAERS reports for methylene blue are dominated by surgical (tissue staining), antidote (methemoglobinemia rescue), and parathyroid-localization use — settings where the drug is given IV in the operating room or ICU, often to patients on multiple other medications. The serotonin syndrome cluster (457 suspect) reflects intra-op IV MB given to surgical patients on chronic SSRI/SNRI therapy — this is real, preventable signal. The hypotension/encephalopathy/cardiac-arrest cluster reflects high-dose IV use in critical-care contexts. Most reported AEs do not generalize to oral supplementation at sub-mg/kg doses, but the mechanism-based interaction risks (serotonergic + G6PD) DO generalize because the pharmacology is dose-route independent for those mechanisms. The cui-bono note: the absence of FAERS signals at oral supplementation doses is largely an absence of surveillance data for that use case, not an established safety profile.

Synergies & Stacking

Antagonisms / Cautions:

• Serotonergic agents (SSRIs, SNRIs, MAOIs, TCAs, triptans, tramadol, meperidine, dextromethorphan, St. John's Wort, linezolid): Hard contraindication for non-emergency MB use. The MAO-A inhibition is potent (Ki ~5 nM, PMID 21422984) and reversible but persists for hours after a single dose. Clinical case literature documents serotonin syndrome at IV doses as low as 0.7 mg/kg in patients on serotonergic agents. FDA mandates 72-hour washout before non-emergency MB. Off-label oral nootropic use in patients on any serotonergic agent is the single most common preventable harm scenario.
• G6PD deficiency: FDA contraindication. Hemolytic anemia. MB cannot complete its redox cycle without NADPH and instead drives oxidative damage to red cells. Test G6PD status before non-emergency use.
• Pregnancy: Contraindicated except for life-threatening methemoglobinemia (intestinal atresia signal in second-trimester amniocentesis exposure).
• Cholinesterase inhibitors (donepezil): Interfere with HMTM's tau-rescue mechanism (PMID 38677558). Theoretical concern for off-label tauopathy use in patients on AD pharmacotherapy.
• Other photosensitizers + bright sunlight: MB is a singlet-oxygen-generating photosensitizer. Concurrent use with porphyrins, some tetracyclines, hypericin at elevated systemic doses with sunlight exposure is a theoretical phototoxicity concern.

Individual Response Modifiers

Sex-Specific Considerations

Genetic Modifiers

Community & Anecdotal Evidence

DISCLAIMER: This section reports anecdotal/community-sourced data (Reddit, Longecity, biohacker YouTube, vendor blogs). Folk evidence is NOT clinical evidence. Cited only to surface user experience patterns and red flags, not to validate efficacy claims.

Source Communities & Sentiment

• Reddit (r/Nootropics, r/Biohackers, r/Supplements, r/longevity): hundreds of threads. Mixed-positive sentiment with strong "placebo or real?" undercurrent. Top complaint: mouth/teeth staining. Most-cited subjective benefit: mental clarity / "after-the-fact learning."
• Longecity (8+ years, multi-page threads e.g. topic 51983/59197/61332/114566): hundreds of posters. Mixed sentiment — long tail of "no effect except blue urine" balanced by enthusiastic 3-month responders. Doses cluster 60 mcg microdose to 15 mg/d.
• YouTube biohacker (Rogan/Gibson, Bryan Johnson, Gary Brecka, Dave Asprey, Huberman shorts, Peter Attia ep 370): high-six-figure to 8-figure viewership. Positive-leaning with notable counterweights — Andrew Huberman publicly stated he has not tried MB and flagged MAO-A inhibition / serotonin-elevating concern. Bryan Johnson publicly STOPPED MB after using it.
• Vendor blogs (Troscriptions, Lost Empire Herbs, Dave Asprey, Ben Greenfield, Meraki Medicinal, Mark Sloan's "Ultimate Guide" book, Gary Brecka's NAD/Ultimate Human ecosystem): strongly positive — commercial bias high. Shared template language across vendors ("0.5–4 mg/kg therapeutic", "5 on / 2 off", "60–90 min before red light", "hormetic curve") suggests echo, not independent observation.
• Mainstream/skeptic press (NPR, CBC White Coat, Conversation/USC, National Geographic, Fortune, MDLinx): negative-cautious. Repeated framing: "no human clinical trial benefit shown"; FDA black-box warning cited universally.

Reported Subjective Effects (community, ranked by frequency)

1. Mental clarity / "after-the-fact learning" (most-cited)
2. Energy / endurance lift (workout output, recovery)
3. Mood lift / mild antidepressant subjective effect
4. Visible blue urine / saliva (universal — community frames as "proof it's working")
5. Improved focus during task
6. Warmer extremities / improved peripheral circulation (low-dose, <1 mg/d)
7. Better digestion
8. Long-activity endurance (3–4 mg every 3–4 days for 1–3 hr hikes/runs)
9. Subjective testosterone/libido lift (heavily vendor-amplified)
10. "Nothing — just blue pee" — non-trivial fraction, especially at microdose

Reported Side Effects

1. Blue/green urine (universal, expected, not bothersome)
2. Mouth, tongue, teeth staining (2–6 hr) — #1 complaint
3. Headache (dose-related)
4. Nausea / GI upset (community remedy: take with meal)
5. Skin discoloration (transient, higher doses)
6. Sleep disruption / jitteriness with PM dosing (community consensus: dose 7–10 AM)
7. Photosensitivity (under-discussed in community vs clinical literature)
8. Neck tension / mild dysautonomia complaints
9. Suspected serotonin toxicity (Longecity case w/ methylphenidate ER; "weird wired feeling" with SSRI overlap)
10. Confusion/dizziness/tremor at higher doses

Folk Dosing vs Clinical

Cycling: 5 days on / 2 days off most common; some run 4 weeks on / 1 week off.

Red Flags & Skepticism Notes

• Troscriptions (Just Blue, Tro+ Blue, 16 mg buccal troche): Trustpilot reports of suspected fake positive reviews, no phone number, offline chat, no self-service cancellation. Co-founders host their own podcast featuring their own products (cui bono = direct).
• Health Ranger Store (Mike Adams): sells MB; political/conspiracy-aligned audience overlap with RFK Jr / Mel Gibson / Joe Rogan. Cui bono = direct + ideologically motivated.
• Mark Sloan, "The Ultimate Guide to Methylene Blue": single-author book promoting MB for depression, COVID, AIDS, Alzheimer's, autism, cancer, heart disease. Breadth of disease claims is a textbook "panacea" red flag.
• Dave Asprey / Bulletproof / Gary Brecka / Ultimate Human / 10X Health: pre-establishes authority for upsell of branded testing/services. Cui bono = direct.
• Shared template language across Asprey, Meraki Medicinal, BetterLife-Lab, Sanare Lab, NooBlue: identical phrasing → shared SEO content sources, not independent practitioner consensus.
• No formal MLM structure surfaced — pattern is influencer affiliate + DTC e-commerce.

Folk vs Clinical Reality Check

Where folk and clinical converge: (a) MAO-A inhibition is real and the SSRI/serotonin syndrome risk is well-documented in both spheres; (b) low-dose oral MB is generally well-tolerated for short periods at 5–30 mg; (c) the hormetic dose-response is supported by preclinical data (though community cites identical numbers across vendor sites, suggesting echo rather than independent observation). Where they diverge sharply: the community treats MB as a cognitive enhancer, mood lifter, longevity agent, and testosterone booster on the strength of preclinical rodent work, n=1 testimonials, and a small handful of underpowered human trials — none of which would survive a rigorous clinical-trial bar. The Bryan Johnson public reversal, Andrew Huberman's explicit "I've never tried it / serotonergic concern" statement, and the consistent NPR/CBC/National Geographic skeptical framing represent the most credible counterweight to vendor-driven hype. The G6PD deficiency screening gap and the SSRI-interaction gap remain the two highest-stakes safety blind spots in routine biohacker self-experimentation.

Deep Dive

Replication Status

The clinical evidence base for oral methylene blue spans distinct domains, each with very different replication characteristics:

• Methemoglobinemia rescue (IV, USP-grade): Replicated across decades of clinical use, multiple case-series, AHA 2023 first-line endorsement (PMID 37721023). High-confidence direct causation.
• Septic shock vasoplegia: Multiple meta-analyses (PMID 38904978 Fernando 2024 SR/MA; PMID 37880041 Pruna 2024; PMID 39965613 Bauer 2025) report point estimate favoring MB for mortality with low-to-moderate certainty due to small individual RCTs and heterogeneous dosing. Surviving Sepsis Campaign does NOT endorse. Active multicenter RCTs ongoing (NCT06481410 Zhejiang n=488; NCT07264543; ChiCTR2300069430). Replication status: probable but not definitive.
• Tau-aggregation inhibitor program (LMTX/LMTM/HMTM): Wischik P2 LMTX positive (PMID 25027327, n=321) → Gauthier 2016 P3 LMTM ITT-failed (PMID 27863809, n=891) → monotherapy subgroup signal → Schwab 2024 (PMID 38677558) cholinesterase-inhibitor interference explanation → HMTM LUCIDITY P3 readout March 2026 (PMID 41570392, TauRx claims positive, independent verification pending). Replication status: contested, single-program.
• Postop delirium prevention: Single 2025 RCT (PMID 40696945) — first human RCT signal beyond AD/TBI. Mechanism (PMID 41298550) attributes effect to neuroinflammation suppression + BBB repair. Awaiting replication.
• Healthy-adult cognitive enhancement: PMID 27077734 (Rodriguez 2016, Radiology) is the most-cited primary-literature anchor — single-dose 280 mg oral MB in 26 healthy adults produced increased insular cortex fMRI activation during a sustained-attention task and a small short-term memory retrieval effect. This is a single-site, single-dose, acute-imaging study; it has not been replicated in an adequately powered chronic-dosing trial measuring durable cognitive endpoints. Supplement-marketing claims of nootropic, mood, anti-aging, or "mitochondrial repair" benefits at chronic oral doses extrapolate from this single fMRI study and from the Atamna mitochondrial-hormesis cell/rodent work — they are not replicated clinical claims.

East Asian Research

The Japanese, Korean, Taiwanese, and Chinese literature on methylene blue 2024–2026 is concentrated in: (a) photodynamic inactivation of pathogens / aPDT (Japan, dental, PMID 38786391; Korea, intranasal nano, PMID 40934788), (b) intraoperative methylene blue staining for sentinel lymph node mapping and parathyroid identification, (c) the Korean redox/disulfide tau mechanism work (PMID 39055157, KBSI/Korea, JACS Au — landmark), (d) Korean LC-QToF-MS analytical method development (PMID 40254552), (e) Chinese drug-delivery nanomedicine (intranasal hydrogels for AD, PMID 38395039), and (f) Chinese septic-shock RCT (ChiCTR2300069430 multicenter, n=100, Zhejiang Univ).

What is notably absent from the East Asian literature is any chronic-dosing oral methylene blue clinical trial program for cognition, depression, or anti-aging endpoints. Given the active sleep, cognition, and longevity research programs in Japan and Korea, this absence is itself informative — if a clear clinical signal at supplementation doses existed, replication would be expected and is not observed. Korean supplement regulation explicitly does NOT permit MB as a functional ingredient.

Contradictions

• LMTX P2 monotherapy effect vs LMTM P3 ITT failures vs HMTM LUCIDITY P3 (claimed positive): Wischik 2015 (P2, PMID 25027327) reported a striking dose-response in monotherapy patients. Gauthier 2016 P3 (PMID 27863809, n=891) failed both co-primary endpoints. Pre-specified monotherapy subgroup signals persisted but post-hoc subgroup analysis is not the same as a replicated primary-endpoint result. The 2024 Schwab finding (PMID 38677558) — cholinesterase inhibitors interfere with HMTM benefit — retrospectively explains the monotherapy signal and informed LUCIDITY design. LUCIDITY HMTM P3 (PMID 41570392, March 2026) reports positive results per TauRx; independent verification is pending. The pharma cui-bono caveat applies: TauRx Therapeutics has financial interest in positive readout, and the program has had repeated discrepancies between press releases and peer-reviewed replication.
• Septic shock mortality benefit vs Surviving Sepsis Campaign non-endorsement: Multiple 2024–2025 meta-analyses report point estimates favoring MB for mortality (RR ~0.81 in pooled septic shock data). The Surviving Sepsis Campaign does NOT explicitly endorse MB as standard-of-care. Reading the meta-analytic signal as established efficacy is premature.
• Mitochondrial-rescue hormesis in humans: The dose-response curve for MB on mitochondrial function is well-characterized in vitro and in rodents. Direct measurement in humans (e.g., via ³¹P-MRS or invasive muscle biopsy ATP measurements) at oral nootropic doses has not produced robust, replicated evidence that the in-vitro hormesis maps onto human cognitive endpoints.
• Photobiomodulation conflation: Some popularizations conflate MB's redox-cycling pharmacology with the photobiomodulation (red/near-infrared LED) literature. They are mechanistically related (both modulate cytochrome c oxidase) but pharmacologically and clinically distinct interventions. A claimed effect for one does not transfer to the other.
• "Blue urine = it's working" framing: Blue urine indicates absorption and excretion, not therapeutic effect. It is a pharmacodynamic marker of exposure, not efficacy.
• Bipolar disorder MRS finding (PMID 39019231) vs depression/mood claims: BD patients showed differential / abnormal neurometabolic response to MB, suggesting MB is not universally mood-protective and may interact differently with bipolar pathophysiology. Caution against blanket "MB for depression" claims.

Ataraxia Verdict (as of 2026-04-29)

Hype Check

The MB biohacker narrative is heavily commercially amplified. Vendor sites (Troscriptions, Lost Empire Herbs, Health Ranger Store, Mark Sloan ecosystem) use shared template language ("0.5–4 mg/kg therapeutic", "hormetic dose-response", "5 on / 2 off cycle") suggesting echo rather than independent practitioner consensus. The most credible counterweights — Bryan Johnson's public discontinuation, Huberman's stated non-use + serotonergic concern, NPR/CBC skeptical framing — are systematically under-amplified by the vendor ecosystem. The strong subjective-effect testimonials (mental clarity, energy, mood) are confounded by visible blue urine providing a powerful unblinding cue (placebo amplification).

Evidence Classification

• Methemoglobinemia rescue: DC, BH 8/9, 5/5. Mature consensus.
• Septic shock vasoplegia: UCC, BH 4/9, 3/5. Multiple meta-analyses, mortality signal, SSC non-endorsement caps confidence.
• Postop delirium: UCC, BH 4/9, 3/5. Single 2025 RCT, mechanism plausible.
• Surgical SLN mapping: DC, BH 7/9, 4/5. Established histologic indication.
• AD (LMTX/LMTM/HMTM): UCC, BH 2–3/9, 2/5. Single-program, contested replication. LUCIDITY P3 awaiting independent verification.
• Healthy-adult cognitive enhancement: UCC, BH 2/9, 1/5. Single fMRI study, not replicated.
• Healthy-adult chronic supplementation for longevity: ME, BH 1/9, 1/5. Mechanistic only.
• Depression: NE, BH 0/9, 1/5. Inadequate evidence; bipolar MRS abnormal.

Evidence Gaps

• No replicated cognitive-enhancement endpoint trial in healthy adults
• No long-term safety data for chronic oral supplementation (>3 mo) at sub-mg/kg doses
• LUCIDITY HMTM P3 result awaiting independent statistical replication
• Limited East Asian cognitive trial data despite active longevity programs
• No rigorous 2024–2026 sex-specific PK study
• No actionable pharmacogenomic data beyond G6PD
• Industrial vs USP-grade contaminant burden in chronic supplementation users undocumented

Bias Flags

• Surrogate endpoint trap: Many 2024–2026 MB papers report mitochondrial/oxidative biomarker improvement (MMP, ROS) without clinical endpoints. Cap claims at 3/5 per vault rules (cf. vitamin E precedent).
• Pharma cui-bono on LMTX/LMTM/HMTM: TauRx Therapeutics has financial interest in positive readout. Repeated discrepancies between press releases and peer-reviewed clinical evidence in this program. Independent statistical verification of LUCIDITY pending.
• Single-author / single-lab dependence: Atamna mitochondrial hormesis lab is the dominant source of preclinical mitochondrial-bypass claims (PMID 18230223). Independent replication thin.
• Replication-failure trap: Reading the LMTM P3 monotherapy subgroup as established efficacy is post-hoc subgroup analysis, not a replicated primary endpoint.

Manipulation Flags

• Vendor astroturf: Troscriptions Trustpilot suspected fake reviews; co-founder podcast hosting their own products. Health Ranger Store ideological alignment.
• Influencer hype economics: Mark Sloan's "panacea" book claiming MB cures depression / COVID / AIDS / Alzheimer's / autism / cancer / heart disease. Dave Asprey / Gary Brecka authority pre-positioning for upsell.
• SEO content templating: Identical dosing/cycling language across multiple unrelated vendor sites suggests purchased SEO content templates, not independent practitioner consensus.
• Cui bono BOTH directions: Vendors profit from popularity ($20–100/bottle USP-grade MB; $50–100 for branded troches like Troscriptions Just Blue). Pharma has limited motivation to fearmonger MB (no patent-rich competitor; LMTM was a pharma-developed derivative, so pharma is INSIDE the MB story, not outside it).
• Supply chain economics: China = >80% global MB manufacturing capacity. USP-grade premium vs lab-grade is a real quality difference AND a vendor marketing lever — buyers should look for COA / third-party heavy-metals testing, not brand claims.

Decision Support (Mode 3 Clarity Compass — stack-agnostic)

• Health utility score: 4–5/10 — strong for methemoglobinemia (rare emergency); modest evidence for septic shock vasoplegia and postop delirium (hospital-only); no clear longevity / chronic cognition signal.
• Opportunity cost: Low financial cost ($20–50/bottle USP-grade); moderate complexity (drug-interaction screen, G6PD test, lab purity verification, blue staining nuisance).
• Hell Yes or No (Sivers test): NOT a Hell Yes for chronic supplementation. Strong evidence is restricted to hospital-IV indications.
• Verdict: CONDITIONAL — defensible only if (a) G6PD-tested; (b) NOT on any serotonergic medication (SSRIs/SNRIs/MAOIs/triptans/tramadol/meperidine/dextromethorphan/St John's Wort/linezolid); (c) USP-grade purity verified by COA; (d) accepting that cognitive/longevity benefit is unproven at chronic supplementation doses. SKIP for healthy adults seeking chronic nootropic effect.
• Regret minimization: In 5 years, the healthy-adult chronic supplementation literature is unlikely to have produced a replicated clinical signal (if it did, it would already be visible). The hospital indications will likely have firmer evidence (multiple ongoing P3 vasoplegia and HMTM trials). Documenting MB now is worthwhile; using it chronically is not.

Bottom Line

Methylene blue is a hospital rescue drug with FDA approval for one rare emergency (acquired methemoglobinemia) and growing evidence for ICU adjunctive use (vasoplegia, postop delirium prevention). The supplement-marketed cognitive enhancement / mitochondrial repair / longevity / antidepressant claims rest on (a) one fMRI study in 26 healthy adults, (b) preclinical rodent mitochondrial hormesis, and (c) extrapolation from the contested LMTX/LMTM/HMTM Alzheimer program. The single most preventable harm is using off-label MB while on serotonergic medications — this is a real, documented, fatal-in-some-cases risk. The G6PD screening gap is the second most important safety blind spot. For healthy adults seeking nootropic / longevity benefit: SKIP at chronic doses; the evidence does not support the marketing claims. For specific medical contexts (methemoglobinemia, vasoplegia under medical supervision, registered tauopathy trials): the evidence supports use within those contexts only.

Practical Notes

Brands and Quality Tiers

• USP-grade pharmaceutical IV solution: Provayblue (NDA204630, Provepharm SAS) and ANDA generics (Meitheal, Zydus, Xiromed, SteriScience, Hikma, Chengdu Shuode, Nexus). Hospital-only.
• USP-grade oral / sublingual (consumer): Troscriptions Just Blue 16 mg buccal troche (~$3–5/dose, ~$50–100/box of 10 troches), Meraki Medicinal, BlueLifeAlpha. Verify USP-NF compliance via COA.
• Lab-grade / chemical-grade: Sigma-Aldrich, ScienceLab. NOT for ingestion. Heavy-metal contamination tolerances higher than pharmaceutical.
• Aquarium / textile-dye grade: Manufactured for non-medical use. Should never be ingested. Common contamination with zinc and lead.

Storage and Stability

• Light-protective container (MB is photoreactive)
• Room temperature; refrigeration not required
• Stable for years if dry; aqueous solutions degrade over months

Cost (consumer USP-grade)

• USP-grade powder ($20–40 / 10 g) — most cost-efficient if user can self-dose accurately
• Pre-made oral solutions / drops ($30–60 / 30 mL @ 1% w/v)
• Branded troches (Troscriptions Just Blue 16 mg) — $50–100 / 10 troches

Reference Ranges and Monitoring

• No validated supplementation biomarker
• Pharmacodynamic markers: blue-green urine and saliva (expected within hours; resolves 1–3 days post-discontinuation)
• For chronic users: pre-screen G6PD; periodic CBC if regular use; pulse oximetry interpretation requires awareness of MB's transient false-desaturation effect during/after dosing

Timing / Circadian Considerations

• Community consensus: dose 7–10 AM (PM dosing reported to disrupt sleep in some users; possibly related to MAO-A inhibition affecting evening monoamine catabolism)
• Pre-workout (3–4 mg, 30–60 min before activity) — community-reported endurance benefit, no clinical trial support

What We Don't Know

• Whether low-dose oral MB produces any replicated cognitive-enhancement signal in healthy adults (current evidence: small, single-site, single-dose fMRI / memory paradigms, not replicated as clinical claims)
• LUCIDITY HMTM P3 independent statistical verification status (TauRx claims positive March 2026; independent re-analysis pending)
• Whether the postop delirium prevention RCT (PMID 40696945) replicates in independent populations
• Long-term safety of chronic daily oral MB at supplementation doses (>3 months) outside trial settings
• Drug-interaction profile beyond well-established MAO-A / serotonergic interaction (e.g., interactions with CYP-metabolized drugs at supraphysiologic doses)
• Whether industrial/lab-grade contaminant burden produces measurable cumulative exposure at chronic supplementation use
• Sex-specific pharmacokinetics (no rigorous 2024–2026 study)
• CYP1A2 polymorphism impact on MB clearance (theoretical only)
• HBV antiviral mechanism and clinical efficacy (NCT06887036 Phase 2 RECRUITING)
• CRS/ICANS adjunct effect in CAR-T toxicity (NCT07169487 Phase 1)

Purity and Quality Control

This section is specific to methylene blue because of a real-world distinction supplement marketing routinely conflates:

• USP-grade / pharmaceutical-grade methylene blue: Compendial purity standards (USP-NF monograph) impose specific limits on heavy-metal contaminants (arsenic, cadmium, mercury, lead), residual solvents, and related substances. Heavy metals ≤10 ppm. The only grade documented for chronic ingestion.
• Lab-grade / chemical-grade / "biological stain" grade: Manufactured for histology and microscopy use. Reported industrial-MB contaminants: 150–400 ppm zinc chloride, 10–50 ppm Pb/As/Hg, residual organic solvents.
• Aquarium / textile-dye grade: Manufactured for non-medical use. Should never be ingested. Common contamination with zinc and lead in aquarium-grade product.

China = >80% global MB manufacturing capacity (Guangdong, Hunan, Henan). The "blue urine" pharmacodynamic marker is the same across grades — it indicates absorption of the methylene blue cation, not purity. A consumer self-experimenting cannot distinguish USP-grade from contaminated lab-grade by colour, taste, or acute response. Buyers should look for Certificate of Analysis (COA) with third-party heavy-metals testing, not brand claims alone.

References

Foundational

• PMID 25027327 — Wischik CM et al. "Tau aggregation inhibitor therapy: an exploratory phase 2 study in mild or moderate Alzheimer's disease." J Alzheimers Dis. 2015;44(2):705-720.
• PMID 27863809 — Gauthier S et al. "Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial." Lancet. 2016;388(10062):2873-2884.
• PMID 18230223 — Atamna H et al. "Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways." FASEB J. 2008;22(3):703-712.
• PMID 21422984 — Ramsay RR, Dunford C, Gillman PK. "Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction." Br J Pharmacol. 2007;152(6):946-951.
• PMID 27077734 — Rodriguez P et al. "Multimodal randomized functional MR imaging of the effects of methylene blue in the human brain." Radiology. 2016;281(2):516-526.

2024–2026 Tau / Alzheimer / Neurodegeneration

• PMID 38909930 — Cranston AL et al. "HMTM rescues synaptosomal glutamate release in tau transgenic mice." Cell Signal. 2024.
• PMID 38677558 — Schwab K et al. "Cholinesterase inhibitors interfere with HMTM benefit (SNARE protein rescue)." Brain Res Bull. 2024.
• PMID 39055157 — Seo DH et al. "MB induces disulfide bond formation between Cys residues on tau (redox-mediated crosslinking)." JACS Au. 2024 (Korean).
• PMID 41226707 — Hale HK et al. "MB attenuates 3-NP-induced striatal mitochondrial dysfunction (Huntington's model)." Int J Mol Sci. 2025.
• PMID 41570392 — Wischik CM et al. "HMTM LUCIDITY Phase 3 in MCI + mild-moderate AD." 2026.
• PMID 32280089 — Shiells H et al. "LMTM Phase 3 in behavioral-variant FTD." 2020.

2024–2026 Septic Shock / Vasoplegia

• PMID 38904978 — Fernando SM et al. "MB in septic shock: SR + meta-analysis." Crit Care Explor. 2024.
• PMID 37880041 — Pruna A et al. "MB meta-analysis RCTs in critically ill / perioperative patients." J Cardiothorac Vasc Anesth. 2024.
• PMID 39965613 — Bauer SR et al. "Adjunctive vasopressors in septic shock; MB possible mortality benefit." 2025.
• PMID 39438181 — Cadd M et al. "Hydroxocobalamin vs MB for post-CPB vasoplegia meta-analysis." J Cardiothorac Vasc Anesth. 2024.
• PMID 41266160 — Spiess BD. "MB within oxidation-reduction dysregulation framework for vasoplegia." Br J Anaesth. 2026.
• PMID 39780053 — Shaker EH et al. "MB in septic cancer patients RCT (high-dose vs low-dose)." BMC Anesthesiol. 2025.
• PMID 39469142 — Luis-Silva F et al. "Pilot RCT: early MB in acute-phase septic shock." Front Med. 2024.

2024–2026 Methemoglobinemia / Toxicology

• PMID 37721023 — AHA 2023 Focused Update: MB first-line antidote 1–2 mg/kg IV for symptomatic methemoglobinemia.
• PMID 40062661 — Rothenberg R, Hoffman RS. "24-year single-center MB experience for methemoglobinemia at NYC Poison Center." Clin Toxicol. 2025.
• PMID 37694789 — Emadi E et al. "Leucomethylene blue (reduced form) as G6PD-safe alternative." Curr Med Chem. 2025.
• PMID 41574980 — Al-Hajjaj R et al. "Methemoglobinemia in infancy review (pediatric G6PD screening)." 2026.

2024–2026 Cognition / Postop Delirium

• PMID 40696945 — Zhang W et al. "Intraoperative MB reduces postop delirium in elderly joint replacement: RCT." Int J Surg. 2025.
• PMID 41298550 — Deng Y et al. "MB reduces postop delirium via neuroinflammation suppression + BBB repair (mouse mechanism)." Sci Rep. 2025.

2024–2026 Malaria / Infection

• PMID 41298347 — Hang JW et al. "MB treatment of fatal cerebral malaria + blood biomarker identification." Nat Commun. 2025.
• PMID 39058023 — Chaumeau V et al. "MB transmission-blocking activity vs P. vivax gametocytes ex vivo." Antimicrob Agents Chemother. 2024.

2024–2026 Cancer / Photodynamic / Surgical

• PMID 38866990 — Carvalho A et al. "MB tattooing for lymph node yield in colon cancer (retrospective multicenter)." Int J Colorectal Dis. 2024.
• PMID 41910280 — Rondelli E et al. "MB for chemoradiotherapy-induced oral mucositis: meta-analysis." J Cancer Res Ther. 2026.
• PMID 40944330 — Zhu et al. "MB for hemorrhoidectomy postop pain." 2025.

2024–2026 Bipolar / Mood

• PMID 39019231 — Russo A et al. "Quantitative neuroimaging in bipolar disorder: altered oxidative neurometabolic response to MB." J Affect Disord. 2024.

2024–2026 Sex Differences / Pharmacogenomics

• PMID 40405864 — Ciardo M et al. "Sex-specific gametocyte response in P. falciparum (parasite, not patient)." J Antimicrob Chemother. 2025.

Methodology / Analytical / East Asian

• PMID 40254552 — Park SJ et al. "Novel LC-QToF-MS method with difluoroacetic acid for MB pharmacokinetic quantification." 2025 (Korean).
• PMID 38786391 — Maruyama et al. "aPDT with MB on tongue dorsum reduces halitosis (RCT, Okayama University)." Healthcare. 2024 (Japanese).
• PMID 40934788 — Han S et al. "Intranasal nanophotosensitizer with MB for broad-spectrum respiratory virus inactivation." 2025 (Korean).
• PMID 38395039 — Liu Y et al. "Intranasal hydrogel MB for AD." Adv Mater. 2024 (Chinese).

Skin / Other

• PMID 38773702 — "Cutaneous heat hyperalgesia at higher MB doses (rat model)."

Trial Registrations

• NCT01689246, NCT01689233 — TRx0237 LMTM Phase 3 in mild-moderate AD (FAILED 2016).
• NCT01626378 — TRx0237 LMTM Phase 3 in bvFTD.
• NCT02245568 — TauRx LMTM Open-Label Extension (TERMINATED).
• NCT06481410 — Severe septic shock RCT (Zhejiang Univ, n=488, RECRUITING).
• NCT07264543 — Early MB in septic shock + hypoperfusion (Phase 2/3, RECRUITING).
• NCT06887036 — Chronic HBV infection (Phase 2, RECRUITING) — novel antiviral indication.
• NCT07169487 — Adjunctive MB for CRS / ICANS (Phase 1, RECRUITING) — CAR-T toxicity application.
• NCT07324954 — TKA prosthetic-joint infection (Phase 1, RECRUITING).
• NCT05894954 — MCI / mild dementia precision-medicine (Phase 3, COMPLETED).
• ChiCTR2300069430 — China multicenter septic shock RCT (n=100, 2023). Protocol PMID 39334256.

Guidelines / Regulatory

• AHA 2023 Focused Update on Cardiac Arrest / Life-Threatening Toxicity (PMID 37721023): MB first-line for methemoglobinemia.
• Surviving Sepsis Campaign: does NOT explicitly endorse MB as standard-of-care.
• FDA Provayblue label NDA204630 (2024-12-02 supplement): boxed warnings 5.1–5.4 (serotonin syndrome, anaphylaxis, lack of effectiveness, G6PD hemolysis); 72-hr serotonergic washout mandate.
• WADA 2025 Prohibited List: MB itself NOT prohibited; IV >100 mL within 12 h of competition prohibited as M2 method; oral/sublingual permitted in/out of competition.